康宁杰瑞制药-B（股票代码：09966）于2026年11月2日公告称，公司在香港联交所场内回购230,000股股份，约占回购前公司已发行股本的0.0238%。根据公告，回购价格介乎每股5.985港元至6.12港元，总成交金额为1,394,105港元，折合约139.41万港元。
公告显示，此次回购完成后，公司已发行股份（不包括库存股份）总数变更为965,921,697股，库存股份数增至8,460,000股。回购授权于2026年6月12日获得股东大会通过，总回购额度为96,850,669股。截至本次回购，已购回2,585,000股，占授权通过当日公司已发行股份（不包括库存股份）总数约0.2669%。
公司同时确认已遵守香港联交所证券上市规则及相关适用法律法规。本次公告由公司执行董事徐霆签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.